BR112021011014A2 - Anticorpos anti-claudina e usos destes - Google Patents
Anticorpos anti-claudina e usos destes Download PDFInfo
- Publication number
- BR112021011014A2 BR112021011014A2 BR112021011014-3A BR112021011014A BR112021011014A2 BR 112021011014 A2 BR112021011014 A2 BR 112021011014A2 BR 112021011014 A BR112021011014 A BR 112021011014A BR 112021011014 A2 BR112021011014 A2 BR 112021011014A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- seq
- region
- ids
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/119797 | 2018-12-07 | ||
| CNPCT/CN2018/119797 | 2018-12-07 | ||
| PCT/CN2019/123588 WO2020114480A1 (en) | 2018-12-07 | 2019-12-06 | Anti-claudin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011014A2 true BR112021011014A2 (pt) | 2021-08-31 |
Family
ID=70975310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011014-3A BR112021011014A2 (pt) | 2018-12-07 | 2019-12-06 | Anticorpos anti-claudina e usos destes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210380680A1 (https=) |
| EP (1) | EP3891183A4 (https=) |
| JP (1) | JP7458399B2 (https=) |
| KR (1) | KR20210100655A (https=) |
| CN (1) | CN113423735B (https=) |
| AU (1) | AU2019391204A1 (https=) |
| BR (1) | BR112021011014A2 (https=) |
| CA (1) | CA3122135A1 (https=) |
| IL (1) | IL283754A (https=) |
| MX (1) | MX2021006681A (https=) |
| SG (1) | SG11202105885WA (https=) |
| WO (1) | WO2020114480A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| CN115943162A (zh) * | 2020-06-19 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗Claudin18.2抗体以及其用途 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| KR20230079096A (ko) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도 |
| US20240034784A1 (en) * | 2020-09-30 | 2024-02-01 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| CN114044822B (zh) * | 2021-10-28 | 2023-06-27 | 杭州博茵生物技术有限公司 | 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用 |
| CN118139888A (zh) * | 2021-11-05 | 2024-06-04 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| CN114395040B (zh) * | 2022-02-09 | 2023-12-15 | 东南大学附属中大医院 | 再生蛋白reg1a单克隆抗体及其应用 |
| WO2023196882A1 (en) | 2022-04-06 | 2023-10-12 | Zai Lab (Us) Llc | Claudin 18.2 immunohistochemistry assay and use thereof |
| CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
| CA3261520A1 (en) * | 2022-07-08 | 2024-01-11 | Telix Targeting Technologies, Inc. | ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE |
| WO2024131683A1 (zh) * | 2022-12-19 | 2024-06-27 | 华润生物医药有限公司 | 结合cldn18.2的抗体和抗体药物偶联物及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
-
2019
- 2019-12-06 JP JP2021532180A patent/JP7458399B2/ja active Active
- 2019-12-06 WO PCT/CN2019/123588 patent/WO2020114480A1/en not_active Ceased
- 2019-12-06 MX MX2021006681A patent/MX2021006681A/es unknown
- 2019-12-06 SG SG11202105885WA patent/SG11202105885WA/en unknown
- 2019-12-06 CN CN201980088317.6A patent/CN113423735B/zh active Active
- 2019-12-06 CA CA3122135A patent/CA3122135A1/en active Pending
- 2019-12-06 US US17/311,307 patent/US20210380680A1/en not_active Abandoned
- 2019-12-06 KR KR1020217020208A patent/KR20210100655A/ko not_active Ceased
- 2019-12-06 AU AU2019391204A patent/AU2019391204A1/en not_active Abandoned
- 2019-12-06 BR BR112021011014-3A patent/BR112021011014A2/pt not_active IP Right Cessation
- 2019-12-06 EP EP19893031.5A patent/EP3891183A4/en not_active Withdrawn
-
2021
- 2021-06-06 IL IL283754A patent/IL283754A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL283754A (en) | 2021-07-29 |
| MX2021006681A (es) | 2021-11-17 |
| KR20210100655A (ko) | 2021-08-17 |
| SG11202105885WA (en) | 2021-07-29 |
| CN113423735A (zh) | 2021-09-21 |
| JP7458399B2 (ja) | 2024-03-29 |
| CN113423735B (zh) | 2024-02-13 |
| CA3122135A1 (en) | 2020-06-11 |
| EP3891183A1 (en) | 2021-10-13 |
| WO2020114480A1 (en) | 2020-06-11 |
| JP2022512132A (ja) | 2022-02-02 |
| AU2019391204A1 (en) | 2021-06-24 |
| US20210380680A1 (en) | 2021-12-09 |
| EP3891183A4 (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7458399B2 (ja) | 抗クローディン抗体及びそれらの使用 | |
| CN116063505B (zh) | 抗gal3抗体及其用途 | |
| JP7084569B2 (ja) | Ｖｉｓｔａ及びその結合パートナーの相互作用を遮断することによる癌治療 | |
| JP6629837B2 (ja) | 抗ｐｔｋ７抗体−薬物コンジュゲート | |
| JP6678941B2 (ja) | 抗体−薬物コンジュゲートのネオアジュバント使用 | |
| WO2019170131A1 (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| CN115427449A (zh) | 抗Gal3抗体和使用方法 | |
| CN105849126A (zh) | 抗trop2抗体－药物偶联物 | |
| CN115998901A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| JP7835441B2 (ja) | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 | |
| CN117897406A (zh) | 抗gal3抗体及其用于胰岛素抵抗的方法 | |
| JP2019525727A (ja) | 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法 | |
| TW201605480A (zh) | 抗ｅｆｎａ４抗體－藥物結合物 | |
| KR20240072932A (ko) | B7-h3에 특이적으로 결합하는 항체 | |
| RU2815926C2 (ru) | Антитела против клаудина и их применение | |
| EP4363456A1 (en) | Anti-alk antibodies & uses thereof | |
| TW202104259A (zh) | 癌治療用醫藥 | |
| HK40059021B (zh) | 抗-紧密连接蛋白抗体及其用途 | |
| HK40059021A (en) | Anti-claudin antibodies and uses thereof | |
| HK40092141A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| HK40090814A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| TW202432186A (zh) | 配體-細胞毒藥物綴合物及其醫藥用途 | |
| IL285313A (en) | Antibodies for cancer treatment | |
| HK40004013A (en) | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2858 DE 14-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |